Cannabidiol

Cannabidiol
Datos Klinikal
Mga tatak pangkalakal	Epidiolex
AHFS/Drugs.com	International Drug Names
Kodigong ATC	Wala ;
Estadong Legal
Estadong legal	AU: S4 (Tanging reseta) ; CA: Iskedyul II ; UK: POM (Tanging reseta) o Suplementong Pangkalusugan; US: Iskedyul I ;
Datos Parmakokinetiko
Bioavailability	13–19% (pambibig), 11–45% (turan 31%; langhap)
Biyolohikal na hating-buhay	9 na oras
Mga pangkilala
	Pangalang IUPAC 2-[(1R,6R)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol;
Bilang ng CAS	13956-29-1 ;
PubChem CID	644019;
IUPHAR/BPS	4150;
ChemSpider	24593618 ;
UNII	19GBJ60SN5;
ChEBI	CHEBI:69478 ;
ECHA InfoCard	100.215.986
Datos Kemikal at Pisikal
Pormula	C21H30O2
Bigat Molar	314.4636
Modelong 3D (Jmol)	Interaktibong larawan;
Punto ng pagkatunaw	66 °C (151 °F)
Punto ng pagkulo	180 °C (356 °F) ; (hangganan: 160–180 °C)
	SMILES Oc1c(c(O)cc(c1)CCCCC)[C@@H]2\C=C(/CC[C@H]2\C(=C)C)C;
	InChI InChI=1S/C21H30O2/c1-5-6-7-8-16-12-19(22)21(20(23)13-16)18-11-15(4)9-10-17(18)14(2)3/h9,12-13,17-18,22-23H,2,5-8,10-11H2,1,3-4H3/t17-,18+/m0/s1 ; Key:ZTGXAWYVTLUPDT-ZWKOTPCHSA-N ;
(ano ito?) (patunayan)

Ang Cannabidiol (CBD) ang isa sa mga 85 cannabinoid na matatagpuan sa halamang cannabis o marijuana.^[5] Ito ang pangunahing sangkap ng halaman na ikalawa sa THC at kumakatawan sa hanggang 40% nito.^[6] Kumpara sa THC, ang cannabidiol ay mas kaunting sikoaktibo at itinuturing na may mas malawak na sakop ng mga paggamot medikal kesa sa THC ^[7] kabilang sa epilepsy,^[8] multiple sclerosis spasms,^[9] anxiety disorders, bipolar Disorder,^[7] schizophrenia,^[10] nausea, kombulsiyon at pamamaga gayundin sa pagpigil ng paglago ng selulang kanser.^[11] Ang Cannabidiol ay nagpakita ng mga epektong sedatibo, pampakalma sa mga pagsubok sa hayop^[12] o kaginhawan ng artritis sa aso.^[12] Ang ibang pagsasaliksik ay nagpapakita na ito ay nagpapataas ng pagiging alerto.^[13] Ang Cannabidiol ay naipakitang nagbawas ng paglago ng mga selulang kanser sa suso in vitro at nagbawas ng kanilang pagsalakay.^[14]

↑ DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml Naka-arkibo 2017-01-17 sa Wayback Machine.; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").
↑ ^2.0 ^2.1 Mechoulam R, Parker LA, Gallily R (November 2002). "Cannabidiol: an overview of some pharmacological aspects". J Clin Pharmacol (Review). 42 (11 Suppl): 11S–19S. doi:10.1177/0091270002238789. PMID 12412831.
↑ Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (May 2009). "Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders". Phytother Res (Review). 23 (5): 597–602. doi:10.1002/ptr.2625. PMID 18844286.
↑ Padron:MEDRS McPartland JM, Russo EB (2001). "Cannabis and cannabis extracts: greater than the sum of their parts?" (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103–132. doi:10.1300/J175v01n03_08. Inarkibo mula sa orihinal (PDF) noong 2017-06-22. Nakuha noong 2013-09-29.
↑ El-Alfy, Abir T; atbp. (2010). "Antidepressant-like effect of delta-9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L." Pharmacology Biochemistry and Behavior. 95 (4): 434–42. doi:10.1016/j.pbb.2010.03.004. PMC 2866040. PMID 20332000. {{cite journal}}: Explicit use of et al. in: |author= (tulong); Unknown parameter |month= ignored (tulong)
↑ Grlić, Ljubiša (1962). "A comparative study on some chemical and biological characteristics of various samples of cannabis resin". Bulletin on Narcotics (3). UNODC: 37–46.
↑ ^7.0 ^7.1 Ashton, C.H., Moore, P. B., Gallagher, P., Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology (U.K).
↑ PMID 22520455 (PubMed)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
↑ PMID 21449980 (PubMed)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand
↑ Zuardi, A.W; J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães (2006). "Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug" (PDF). Braz. J. Med. Biol. Res. 39 (4): 421–429. doi:10.1590/S0100-879X2006000400001. PMID 16612464.{{cite journal}}: CS1 maint: multiple names: mga may-akda (link)
↑ Mechoulam, R.; M. Peters, Murillo-Rodriguez (21 Aug 2007). "Cannabidiol - recent advances". Chemistry & Biodiversity. 4 (8): 1678–1692. doi:10.1002/cbdv.200790147. PMID 17712814.^{[patay na link]}
↑ ^12.0 ^12.1 aPawesomeLife, "Will CBD oil help my dog’s arthritis and joint pain?^{[patay na link]}" thru studies extracted from AKC Canine Health Foundation (2017), Cornell University College of Veterinary Medicine (2018), and American Veterinary Medical Association (2021)
↑ Nicholson, AN; C Turner, BM Stone, and PJ Robson (2004). "Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults" (PDF). J Clin Psychopharmacol. 24 (3): 305–13. doi:10.1097/01.jcp.0000125688.05091.8f. ISSN 0271-0749. PMID 15118485. {{cite journal}}: Unknown parameter |month= ignored (tulong)CS1 maint: multiple names: mga may-akda (link)
↑ McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). "Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells". Mol. Cancer Ther. 6 (11): 2921–7. doi:10.1158/1535-7163.MCT-07-0371. PMID 18025276.{{cite journal}}: CS1 maint: multiple names: mga may-akda (link)

[1] DEA News Release, DEA Eases Requirements for FDA Approved Clinical Trials on Cannabidiol (December 23, 2015) ("CBD is a Schedule I controlled substance as defined under the CSA."), http://www.dea.gov/divisions/hq/2015/hq122315.shtml Naka-arkibo 2017-01-17 sa Wayback Machine.; Joseph T. Rannazzisi Deputy Assistant Administrator Drug Enforcement Administration Before the Caucus on International Narcotics Control, United States Senate, at 2 (June 24, 2015) (CBD is a Schedule I drug.); see also Frank Robison, Elvira Strehle-Henson, Cannabis Laws and Research at Colorado Institutions of Higher Education, COLO. LAW., OCTOBER 2015, AT 73, 76 ("[T]the DEA's position on CBD is clear—it is a Schedule I substance.").

[Mechoulam2002-2] 2.0 ^2.1 Mechoulam R, Parker LA, Gallily R (November 2002). "Cannabidiol: an overview of some pharmacological aspects". J Clin Pharmacol (Review). 42 (11 Suppl): 11S–19S. doi:10.1177/0091270002238789. PMID 12412831.

[Scuderi2009-3] Scuderi C, Filippis DD, Iuvone T, Blasio A, Steardo A, Esposito G (May 2009). "Cannabidiol in medicine: a review of its therapeutic potential in CNS disorders". Phytother Res (Review). 23 (5): 597–602. doi:10.1002/ptr.2625. PMID 18844286.

[4] Padron:MEDRS McPartland JM, Russo EB (2001). "Cannabis and cannabis extracts: greater than the sum of their parts?" (PDF). Journal of Cannabis Therapeutics. 1 (3/4): 103–132. doi:10.1300/J175v01n03_08. Inarkibo mula sa orihinal (PDF) noong 2017-06-22. Nakuha noong 2013-09-29.

[5] El-Alfy, Abir T; atbp. (2010). "Antidepressant-like effect of delta-9-tetrahydrocannabinol and other cannabinoids isolated from Cannabis sativa L." Pharmacology Biochemistry and Behavior. 95 (4): 434–42. doi:10.1016/j.pbb.2010.03.004. PMC 2866040. PMID 20332000. {{cite journal}}: Explicit use of et al. in: |author= (tulong); Unknown parameter |month= ignored (tulong)

[Grlic_1962-6] Grlić, Ljubiša (1962). "A comparative study on some chemical and biological characteristics of various samples of cannabis resin". Bulletin on Narcotics (3). UNODC: 37–46.

[Ashton,_C.H._2005-7] 7.0 ^7.1 Ashton, C.H., Moore, P. B., Gallagher, P., Young, A. H. (2005). Cannabinoids in bipolar affective disorder: a review and discussion of their therapeutic potential. Journal of Psychopharmacology (U.K).

[8] PMID 22520455 (PubMed)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

[9] PMID 21449980 (PubMed)
Citation will be completed automatically in a few minutes. Jump the queue or expand by hand

[Zuardi-2006-10] Zuardi, A.W; J.A.S. Crippa, J.E.C. Hallak, F.A. Moreira, F.S. Guimarães (2006). "Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug" (PDF). Braz. J. Med. Biol. Res. 39 (4): 421–429. doi:10.1590/S0100-879X2006000400001. PMID 16612464.{{cite journal}}: CS1 maint: multiple names: mga may-akda (link)

[recentadvances-11] Mechoulam, R.; M. Peters, Murillo-Rodriguez (21 Aug 2007). "Cannabidiol - recent advances". Chemistry & Biodiversity. 4 (8): 1678–1692. doi:10.1002/cbdv.200790147. PMID 17712814.^{[patay na link]}

[pmid6269680-12] 12.0 ^12.1 aPawesomeLife, "Will CBD oil help my dog’s arthritis and joint pain?^{[patay na link]}" thru studies extracted from AKC Canine Health Foundation (2017), Cornell University College of Veterinary Medicine (2018), and American Veterinary Medical Association (2021)

[13] Nicholson, AN; C Turner, BM Stone, and PJ Robson (2004). "Effect of Delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults" (PDF). J Clin Psychopharmacol. 24 (3): 305–13. doi:10.1097/01.jcp.0000125688.05091.8f. ISSN 0271-0749. PMID 15118485. {{cite journal}}: Unknown parameter |month= ignored (tulong)CS1 maint: multiple names: mga may-akda (link)

[pmid18025276-14] McAllister SD, Christian RT, Horowitz MP, Garcia A, Desprez PY (2007). "Cannabidiol as a novel inhibitor of Id-1 gene expression in aggressive breast cancer cells". Mol. Cancer Ther. 6 (11): 2921–7. doi:10.1158/1535-7163.MCT-07-0371. PMID 18025276.{{cite journal}}: CS1 maint: multiple names: mga may-akda (link)

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]

[9]

[10]

[11]

[12]

[13]

[14]

Cannabidiol

From Wikipedia, the free encyclopedia · View on Wikipedia